Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Early Phase 1
3(75.0%)
Phase 1
1(25.0%)
4Total
Early Phase 1(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07334574Phase 1Not Yet Recruiting

Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL

Role: collaborator

NCT06496373Early Phase 1Recruiting

Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer

Role: collaborator

NCT06980155Early Phase 1Recruiting

XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia

Role: collaborator

NCT05916248Early Phase 1Recruiting

Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors

Role: collaborator

All 4 trials loaded